Anzeige
Mehr »
Mittwoch, 29.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A412LU | ISIN: US00791X2099 | Ticker-Symbol:
NASDAQ
27.10.25 | 21:00
0,896 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AEON BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
AEON BIOPHARMA INC 5-Tage-Chart

Aktuelle News zur AEON BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
AEON BIOPHARMA Aktie jetzt für 0€ handeln
08.09.AEON Biopharma, Inc. - 8-K, Current Report 2
12.08.AEON Biopharma, Inc. - 10-Q, Quarterly Report1
12.08.AEON Biopharma, Inc. - 8-K, Current Report1
13.06.AEON Biopharma, Inc. - 8-K, Current Report1
11.06.AEON Biopharma, Inc. - 10-Q/A, Quarterly Report1
11.06.AEON Biopharma, Inc. - 10-K/A, Annual Report1
23.05.AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711190IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex...
► Artikel lesen
20.05.AEON Biopharma, Inc. - 8-K, Current Report1
15.05.AEON Biopharma GAAP EPS of $2.281
14.05.AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update179- Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)...
► Artikel lesen
25.04.AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance715IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex...
► Artikel lesen
21.04.AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711140IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex...
► Artikel lesen
21.04.AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer740IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex...
► Artikel lesen
24.03.AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update445- Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)...
► Artikel lesen
24.02.AEON Biopharma, Inc. Announces Reverse Stock Split252IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under...
► Artikel lesen
07.02.AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards240IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under...
► Artikel lesen
13.11.24AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update233- Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA)...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1